Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
95 hedge funds and large institutions have $1.22B invested in Verona Pharma in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 39 increasing their positions, 21 reducing their positions, and 13 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 21
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
65% more call options, than puts
Call options by funds: $3.52M | Put options by funds: $2.14M
8% more funds holding
Funds holding: 88 → 95 (+7)
0.3% more ownership
Funds ownership: 9.26% → 9.56% (+0.3%)
7% less capital invested
Capital invested by funds: $1.31B → $1.22B (-$90.4M)
13% less funds holding in top 10
Funds holding in top 10: 16 → 14 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$53.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$32.3M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$20.8M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$20.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$46.4M |
| 2 |
Janus Henderson Group
London,
|
-$6.81M |
| 3 |
O
OrbiMed
New York
|
-$6.73M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.32M |
| 5 |
ACM
Aisling Capital Management
New York
|
-$4.69M |
VRNA Hedge Fund Activity: Q1 2023 in Review
95 of the 6,246 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q1 2023, worth a combined $1.22B — down 6.9% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new VRNA positions and 13 closed out — a net gain of 9 holders — while 39 added to existing stakes and 21 trimmed.
The largest buyer was Carlyle Group, opening a new position worth an estimated $53.1M. The largest seller was Perceptive Advisors, cutting an estimated $46.4M.
- 95 institutional investors held Verona Pharma (VRNA) as of Q1 2023, up from 88 in Q4 2022.
- Funds reported $1.22B of Verona Pharma stock for Q1 2023, down 6.9% quarter-over-quarter.
- 22 funds opened new Verona Pharma positions in Q1 2023 and 13 closed out, a net change of +9 holders.
- The largest Verona Pharma buyer in Q1 2023 was Carlyle Group, an estimated $53.1M added.
- The largest Verona Pharma seller in Q1 2023 was Perceptive Advisors, an estimated $46.4M sold.
Based on aggregated 13F filings for Q1 2023.